# A Study to Compare Setidegrasib (ASP3082) With Docetaxel, in People With Non-small Cell Lung Cancer With a KRAS G12D Mutation

> **NCT07566052** · PHASE3 · NOT_YET_RECRUITING · sponsor: **Astellas Pharma Global Development, Inc.** · enrollment: 356 (estimated)

## Conditions studied

- Non-small Cell Lung Cancer (NSCLC)

## Interventions

- **DRUG:** Setidegrasib
- **DRUG:** Docetaxel

## Key facts

- **NCT ID:** NCT07566052
- **Lead sponsor:** Astellas Pharma Global Development, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-04-30
- **Primary completion:** 2030-06-30
- **Final completion:** 2030-06-30
- **Target enrollment:** 356 (ESTIMATED)
- **Last updated:** 2026-05-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07566052

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07566052, "A Study to Compare Setidegrasib (ASP3082) With Docetaxel, in People With Non-small Cell Lung Cancer With a KRAS G12D Mutation". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT07566052. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*